Dormant
KMTS · Kestra Medical Technologies, Ltd.
Last analysed ·
Resolved Graded and closed 2026-09-11 at low conviction — the published kill line fired. Coverage continued after the close; the read below is dated 2026-09-13 and is not part of the scored record.
Current thesis
WCD share-capture story intact on fundamentals — FY26 revenue $95.1M (+59%), fiscal Q4 gross margin 54.8% — but the bid has thinned: the close was $25.64 on 2026-08-28, 9.6% under the $28.35 52-week high, with RSI(14) at 13.5 against 67.8 on 2026-08-21 and no dated news in between. The 2026-09-14 Q1 FY27 print is the first test of the $137M FY27 guide (+44%, a deceleration).
Kill line
A weekly close below $24 marks the post-guidance advance as failed, roughly 15% under the $28.35 52-week high. Secondary: the 2026-09-14 Q1 FY27 print comes and goes with the $137M guide reiterated rather than raised and ASSURE prescription growth well under the +63% YoY of fiscal Q4.
Pick status
Invalidated resolved published kill line fired How this is scored →Latest analysis and events for KMTS —
As of 13 September 2026, the latest FrontierPicks analysis for Kestra Medical Technologies, Ltd. (KMTS): WCD share-capture story intact on fundamentals — FY26 revenue $95.1M (+59%), fiscal Q4 gross margin 54.8% — but the bid has thinned: the close was $25.64 on 2026-08-28, 9.6% under the $28.35 52-week high, with RSI(14) at 13.5 against 67.8 on 2026-08-21 and no dated news in between. The 2026-09-14 Q1 FY27 print is the first test of the $137M FY27 guide (+44%, a deceleration).
Kill line: A weekly close below $24 marks the post-guidance advance as failed, roughly 15% under the $28.35 52-week high. Secondary: the 2026-09-14 Q1 FY27 print comes and goes with the $137M guide reiterated rather than raised and ASSURE prescription growth well under the +63% YoY of fiscal Q4.
Most recent dated event on file: — catalyst 6d ago.
Current Thesis
Kestra Medical Technologies’ wearable-defibrillator share-capture thesis has lost its published price support; the 2026-09-14 results test whether operating growth still supports the business case. The 2026-09-11 adjusted close of $22.85 breached the $24 weekly-close condition published on 2026-08-30. That invalidation has occurred before earnings.
For the previously published advance, the narrative is dead — the week ended 2026-09-11 closed below its stated thesis-break level. This is an assessment of the price structure, not evidence that product demand has collapsed. Kestra’s 2026-07-14 release attributed revenue growth to market-share gains and expansion of the wearable cardioverter defibrillator (WCD) market. Company results.
The earnings date is now company-confirmed: Kestra announced on 2026-08-31 that fiscal first-quarter results would arrive after the market closes on 2026-09-14. The earlier calendar uncertainty is resolved. Scheduling announcement.
Bullish and bearish views on Kestra Medical Technologies, Ltd.
The model's bull view on Kestra Medical Technologies, Ltd. (KMTS), in brief: Prescription demand supports reported growth. The bear view: Price invalidation preceded the catalyst. Both cases follow in full.
Bull Case
- Prescription demand supports reported growth. For the quarter ended 2026-04-30, Kestra reported 6,357 ASSURE prescriptions, up 63% year over year, and revenue of $28.6 million, up 66%, in its 2026-07-14 release.
- Gross margin improvement is measured. Fiscal fourth-quarter gross margin reached 54.8%, versus 44.3% a year earlier, according to the 2026-07-14 results.
- Annual guidance still implies expansion. On 2026-07-14, management guided fiscal 2027 revenue to $137 million, representing 44% growth. These operating figures support the commercial case, although the September price breach has already ended the published advance thesis. Company results.
Bear Case
- Price invalidation preceded the catalyst. The 2026-09-11 close of $22.85 finished below the previously published $24 weekly threshold; the 2026-08-28 reference close had been $25.64.
- Growth guidance implies slower expansion. Management’s 44% fiscal 2027 revenue-growth forecast, issued 2026-07-14, compares with reported fiscal 2026 growth of 59%.
- Annual losses continued to widen. Kestra reported a fiscal 2026 net loss of $131.6 million, versus $113.8 million for fiscal 2025, on 2026-07-14. Higher gross margin had not produced annual profitability. Company results.
Setup & Price Structure
The supplied adjusted market series records a $22.85 close on 2026-09-11, 19.4% below its $28.35 52-week high, despite a positive three-month price change of 9.6%. Its 14-period relative strength index (RSI) was 18.6. That momentum reading does not establish a reversal; the observable structural event is the weekly breach of $24.
Analyst attention persisted during the decline. Benzinga’s 2026-09-11 preview reported that BTIG maintained its $32 analyst price target on 2026-09-02 and cited quarterly revenue consensus of $29.01 million. The reiteration and earnings preview document coverage, but this sample is too small to support a retail-crowding claim. No moving-average distance or quantified fund-flow evidence is available here. Benzinga preview.
Catalyst Calendar (next 30 days)
No upcoming dated catalysts on file — the dated entries below have passed.
Elapsed catalysts
- 2026-09-14 — Fiscal first-quarter results. Kestra’s 2026-08-31 announcement confirms publication after the market close and a conference call at 4:30 p.m. Eastern Time. Revenue, prescriptions and updated guidance provide the next operating test; the scheduled report does not reverse the price invalidation already recorded. Company announcement. (passed 6d ago)
What Would Change Our Mind
The post-guidance advance has already lost its published structural condition: a weekly close below $24 occurred with the $22.85 close on 2026-09-11. The threshold remains unchanged for the dated record.
A subsequent weekly close above $24, accompanied by a fiscal 2027 revenue-guidance increase above the $137 million announced on 2026-07-14, would supply evidence for a separate recovery thesis. A guidance reduction at the 2026-09-14 report would instead weaken the remaining operating case. Neither outcome would erase the earlier breach.
Correlation Notes
This remains a single-name setup. No matched peer-return series or measured sector correlation accompanies the 2026-09-11 price observations, so neither a medtech group explanation for the decline nor a group-led recovery claim is supported. The next company-confirmed event is Kestra’s own 2026-09-14 earnings report.
Notes
- Fiscal year ends April 30. 'FY27' covers May 2026-April 2027; quarterly results have landed in September, December, March and July.
- 58,602,497 common shares outstanding as of 2026-07-09 per the FY26 annual report cover page.
- Essentially all revenue derives from the ASSURE WCD system and its associated monitoring service - single-product concentration.
- Several executives sell under pre-adopted 10b5-1 plans; the July-August 2026 Form 4/144 flow is scheduled rather than discretionary.
- Bain Capital is the largest holder at roughly 46% of shares outstanding per August 2026 ownership tallies.
- The 2026-09-14 earnings date comes from third-party calendars; the company had not issued its own scheduling release as of 2026-08-30.
Related · shared themes
TXG
10x Genomics, Inc.
10x Genomics' Atera recovery now needs deliveries and revenue confirmation after clearing its earlier price hurdle. Approximately 40 second-half 2026 shipments and full-year revenue of $610–630 million would substantiate the case before a weekly close below $58.57 invalidates the structure.
ITGR
Integer Holdings Corporation
Integer Holdings Corporation’s $127.00 cash acquisition by KKR remains a completion thesis, strengthened by the 2026-09-03 merger proxy. Completion by year-end 2026 would settle the case; a daily close below $118 invalidates it.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
VREX
Varex Imaging Corporation
Varex Imaging Corporation’s $18.90 cash acquisition by Teledyne remains a completion thesis. The 2026-09-08 preliminary proxy advances the process; payment resolves the case, while a daily close below $17.50 invalidates it.
See also · stocks to watch